Inhaled Dry Powder Combinations For Pulmonary Fibrosis

News

• eSpraye Unveils Phase 2b Study Design for Inhaled Dry Powder Ensifentrine + Nintedanib DPI Combination for Pulmonary Fibrosis - Adds ONCE DAILY Nintedanib ArmOctober 5, 2026
• MERCK's NEXT COPD READOUT COULD RESHAPE THE "FENTRINE" RACESeptember 8, 2026
• eSpraye is Raising a $100 Million Series A to Advance our Lead Program (Ensifentrine + Nintedanib) to Phase 3 Readiness for Pulmonary FibrosisSeptember 1, 2026
• DPI May Reset the Inhaled Dose Equation in Pulmonary FibrosisAugust 4, 2026
• eSpraye’s First Published Patent Applications Signal Broader Platform PlayAugust 2, 2026
• THE FENTRINE CHASE IS ON !!July 8, 2026
• United Therapeutics TreSMI™ TYVASO® Soft Mist Inhaler ?May 22, 2026
• eSpraye CSO Dr. John Patton and Formulation Development Lead Dr. Dan Miller, dive deep into the particle engineering behind eSpraye’s inhaled dry powder formulations in a Q&A session with Dr. Adil Ali, Onyx NewsroomMay 14, 2026
• INHALATION HAS ARRIVED IN PULMONARY FIBROSIS - NEXT COMES COMBINATIONS THERAPIES!April 29, 2026
• Congratulations Avalyn on your Breakout IPO!April 24, 2026
• Avalyn's Nebulizer-First Narrative Is Marketing Dressed as AnalysisApril 9, 2026
• eSpraye Is Built for Where Pulmonary Fibrosis Treatment Is HeadedMarch 24, 2026
• United Therapeutics Kneecaps MannKind with TreSMI Soft Mist Inhaler RevealMarch 15, 2026
• If the disease is in the lungs, why deliver the drugs everywhere else?February 2, 2026